Idorsia Pharmaceuticals Ltd

We were delighted to attend, for the first time, a meeting on autism: the International Society for Autism Research (INSAR) 2026 Congress in Prague, which brought together nearly 2,500 participants. For Ozgur Yuksel, MD, Global Medical Lead for Insomnia at Idorsia and myself, it was a valuable opportunity to engage with leading experts on insomnia, clinical presentations, and endpoints in both children and adults with autism spectrum disorder. Martine Clozel, Chief Scientific Officer and Head of Research. #INSAR2026

Idorsia has issued an invitation to its upcoming AGM. The meeting will be held on Wednesday, May 6, 2026, at 14.00 CEST. Find the invitation together with a supplement with the biographies of the new Board candidates and other relevant material at https://bit.ly/4mmhaqc

Thank you to everyone who joined us at EPA 2026 this week! From the symposium discussions to the many engaging conversations we've held at booth #36, we’ve valued the chance to connect with our fellow experts and continue to advance understanding of managing insomnia in complex psychiatric profiles. We're looking forward to sharing our insights and continuing these important discussions throughout the year. #EPA2026 #Insomnia #Pharmaceuticals

Idorsia announces positive Phase 2 results for its investigational drug for children with insomnia disorder. The study showed dose‑dependent, clinically meaningful improvements across multiple sleep measures and confirmed the safety and tolerability profile of the drug for the first time in a pediatric population. Martine Clozel, MD, Pediatrician, Chief Scientific Officer & Head of Research of Idorsia says: “We are not only helping young patients and their families – who urgently need evidence-based treatments when children suffer from chronic insomnia – but we are also seeing new signals that the orexin system may play an even more important role in neurodevelopmental disorders than previously understood.” These exploratory Phase 2 data will now be discussed with health authorities as we work to define the next steps in the pediatric development program. Full results will be presented at upcoming scientific meetings and published in peer‑reviewed journals. Read the media release: https://lnkd.in/evzvxkiQ

Today at EPA 2026, we're proud to be sponsoring a dedicated symposium exploring the urgent need for action and provide practical, evidence-based guidance for managing insomnia in complex psychiatric profiles. Chaired by Prof. Andrea Fiorillo, our 90‑minute session brings together leading experts to explore: - Insomnia disorder: Why psychiatrists must act now - Managing insomnia disorder in complex psychiatric profiles: From anxiety to substance use disorder - Targeting the wake system - Real-world evidence: Insomnia disorder in patients with anxiety, depression, or substance use disorders - Clinical case: Practical management of insomnia disorder in a psychiatric patient Join us in the Forum Hall on the 2nd floor from 13:15 - 14:45 CEST for a rich and important discussion. We look forward to seeing you there! #EPA2026 #Psychiatry #Insomnia #Pharmaceuticals

Today at EPA 2026 we are proud to exhibit our commercial & medical booth as a space for meaningful dialogue with clinicians and mental health professionals on advancing psychiatric care — particularly around insomnia and complex psychiatric profiles. If you’re attending EPA 2026, stop by booth #36 to continue the conversation. #EPA2026 #Psychiatry #Insomnia #SleepMedicine #MentalHealthCare #Pharmaceuticals

We are excited to be attending the 34th European Congress of Psychiatry (EPA 2026) in Prague from 28–31 March. This year’s motto – “Mental Health: Improving Care and Expanding Horizons” – highlights the importance of strengthening collaboration, advancing scientific understanding and driving better mental healthcare for people across Europe. At Idorsia, we are committed to challenging accepted medical paradigms and deepening scientific insight across our portfolio. We look forward to connecting with colleagues, exchanging ideas and contributing to conversations that aim to improve access for all. #EPA2026 #MentalHealth #Pharmaceuticals

Celebrating World Sleep Day 2026 – Sleep Well, Live Better. Today, we were proud to bring together more than 100 colleagues onsite and many more joining via global livestream for a special employee event dedicated to World Sleep Day 2026. The session focused on a topic that touches millions: insomnia. We had the privilege of hearing real patient stories describing the profound burden that chronic insomnia places on daily life – and the incredible difference that a restorative night’s sleep can make. Their experiences were a powerful reminder of why we do what we do. Quality sleep is essential to health, wellbeing, and the ability to thrive – and we remain committed to supporting better sleep and revitalized days for people around the world. Thank you to everyone who joined, contributed, and helped make this event meaningful and for our great speakers who inspired us. Together, let’s continue to advance the science and awareness of healthy sleep. #WorldSleepDay #SleepWellLiveBetter #EmployeeEngagement #TeamIdorsia

For many women in midlife, #InsomniaDisorder is not just an inconvenience – it can quietly impact health, confidence and performance at work. Despite pushing through exhaustion to meet the demands of their careers and personal lives, many still face limited understanding and support in the workplace. This #WorldSleepDay, by bringing forward new insights from women living with insomnia disorder we hope to spark greater understanding and encourage meaningful conversations about the critical role of sleep in midlife health and workplace equity. At Idorsia, we are committed to supporting the global sleep community and advancing awareness of insomnia disorder as a chronic and treatable medical condition. Read our CEO Srishti Gupta’s article to learn more about the hidden impact of persistent sleep loss on women in midlife. #SleepAwareness #SleepHealth

For many women in midlife, the impact of persistent sleep loss is carried into the workplace. Sleepless nights can affect concentration, performance and working hours – often in silence. New findings from our Insomnia Disorder in Midlife Women Survey, of over 1,400 women experiencing insomnia disorder aged 40-60 across 9 countries, help bring these experiences to light. These findings raise an important question: how often do women’s health conversations recognize how sleepless nights impact the working day, affecting daytime functioning and productivity? That’s why this #WorldSleepDay, we’re proud to join the World Sleep Society in supporting this year’s theme “Sleep well, live better”, to help elevate the much-needed conversations around sleep health. It’s time to Rethink Insomnia – to learn more about insomnia disorder and hear real-life stories, visit: https://bit.ly/4lqMowb #WorldSleepDay #InsomniaDisorder #RethinkInsomnia